NICE Updates Type 2 Diabetes Guidance for Earlier SGLT-2 Inhibitor Use; SGLT2 Inhibitors Also Linked to Survival Benefit in Takotsubo Syndrome

Millions of people living with type 2 diabetes could gain earlier access to life-extending treatments under new NICE recommendations for England. Separately, new real-world data published in The American Journal of Cardiology found that early use of SGLT2 inhibitors can help patients with Takotsubo syndrome (TTS), or "broken heart syndrome," live longer.

The updated NICE guidance marks a clear shift away from a predominantly glycaemia-driven escalation model towards a proactive, personalised strategy that prioritises cardio-renal-metabolic risk. Treatment with medication is now stratified according to key clinical characteristics rather than HbA1c alone. NICE states that clinicians should assess each patient for established atherosclerotic cardiovascular disease (ASCVD), heart failure, chronic kidney disease (CKD), obesity, early-onset type 2 diabetes (diagnosed before age 40), and frailty prior to initiating treatment.

A major development is the earlier use of SGLT-2 inhibitors. NICE now recommends these agents as part of initial dual therapy, along with modified-release metformin for most people, or as monotherapy where metformin is unsuitable. The guidance recommends metformin + an SGLT-2 inhibitor from the start for most people, with a slow-release version of metformin to reduce stomach upset. Earlier introduction of SGLT-2 inhibitors reflects clinical trial evidence demonstrating reductions in heart failure hospitalisation and slower progression of CKD, with benefits that extend beyond glycaemic control.

The guidance also elevates GLP-1 receptor agonists like semaglutide (Ozempic) and the dual GLP-1/GIP receptor agonist tirzepatide within the treatment pathway. Earlier use of these medications, often alongside metformin and SGLT-2 inhibitors, is now recommended for people with ASCVD, obesity, or early-onset type 2 diabetes, where weight reduction and cardiovascular risk modification are priorities. These are no longer restricted to use only after triple therapy or if the patient has a BMI >35 kg/m². Up to 810,000 more people could become eligible for GLP-1 receptor agonists and tirzepatide under the new guidance.

NICE analysis estimates that using SGLT-2 inhibitors earlier, together with GLP-1 receptor agonists and tirzepatide for specific groups, could prevent around 17,000 deaths over three years across the UK. Heart disease remains the leading cause of death among people with type 2 diabetes. The NHS is expected to save £560 million over 2025/26 and 2026/27 thanks to the availability of generic dapagliflozin, a widely used SGLT-2 inhibitor.

NICE reviewed anonymised records from nearly 590,000 people and found that SGLT-2 inhibitors are not prescribed equally across different groups. The data showed underprescribing among women, older adults, and black people. New recommendations ask NHS services to monitor prescribing patterns and take action to reduce inequalities.

In a separate research development, a study tracked data from nearly 55,000 patients with Takotsubo syndrome who underwent treatment from 2015 to 2025. Patients were propensity matched into two groups of 1,803 patients — one group that received SGLT2 inhibitor therapy within 14 days and another group that did not. Overall, the SGLT2 inhibitor patients were associated with a significantly lower all-cause mortality rate (8.1% vs. 13.6%). There were no significant differences in terms of heart failure hospitalizations, cardiogenic shock, cardiac arrest or major adverse cardiovascular events. The authors noted that SGLT2 inhibitors could still be linked to certain benefits related to heart failure symptoms, even after no difference was seen in heart failure hospitalization rates. The researchers called for additional research, stating that the data is hypothesis-generating and supports the need for randomized trials to evaluate the role of SGLT2 inhibitors and other cardioprotective therapies in patients with TTS.